Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide.

Antagonistic activity of Streptomyces gresiofuscus PTCC1628 against isolated Gram negative bacteria from Urinary Tract Infections

  Antibiotics are the best known products of actinomycete. Over 5,000 antibiotics have been identified from the cultures of Gram positive and Gram-negative organisms, and filamentous fungi, but only about 100 antibiotics have commercially been used to treat human, animal and plant diseases. The genus, Streptomycete, is responsible for the formation of more than 60% of known antibiotics. Bacteri...

Oritavancin microbiologic features and activity results from the surveillance program in the United States.

Oritavancin is in the final stages of clinical development for treatment of acute bacterial skin and skin structure infections. This drug has demonstrated potent activity against staphylococci (minimum inhibitory concentration [MIC] for which 90% of isolates are inhibited [MIC(90)], 0.06 μg/mL), enterococci (MIC(90), ≤ 0.008 to 0.5 μg/mL), and streptococci (MIC(90), ≤ 0.008 to 0.12 μg/mL), incl...

Efficacy of Amikacin and Imipenem Against Multi-Drug Resistant Gram-Negative Bacteria Isolated From Wound Infections

Background and Objective: Gram-negative pathogens are considered the common cause of wound infections associated with increased mortality and morbidity rates. Antibiotics combination has been used to overcome this problem. Aims: In this study, we identify Gram-negative pathogens found in wound infections and assess the in-vitro efficacy of a combination of amikacin and imipenem against the resi...

Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008–2016)

Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections

Oritavancin, a semisynthetic derivative of the glycopeptide antibiotic chloroeremomycin, received the US Food and Drug Administration approval for the treatment of acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria in adults in August 2014. This novel second-generation semisynthetic lipoglycopeptide antibiotic has activity against a broad spectrum of...